MOTS-c long term side effects: what's known, what isn't

Last updated 2026-07-24

What are the long term side effects of MOTS-c in humans?

The honest answer is that nobody knows, because the long-term human studies don't exist yet. Every one of the roughly 30 studies on MOTS-c cited in this article is either a rodent experiment, a cell-culture experiment, or a mechanistic review. None is a multi-month or multi-year human safety trial. The foundational MOTS-c paper, published in Cell Metabolism in 2015, showed that the peptide promotes metabolic homeostasis and reduces obesity and insulin resistance in mice ^[1]. That's a real finding, and it's the reason MOTS-c gets attention at all. But it's a mouse study. A 2023 Frontiers in Endocrinology review calls MOTS-c 'a promising mitochondrial-derived peptide for therapeutic exploitation,' which is accurate but also a tell: 'promising for exploitation' is review-speak for 'not yet proven in people' ^[2]. A 2026 Sports Medicine paper reviewing peptide therapies used for musculoskeletal injuries and athletic performance, including unapproved peptides sold in that space, is one of the few sources that directly addresses safety and efficacy of these compounds as used in practice rather than in a lab dish ^[3]. That paper's existence tells you something: peptides like MOTS-c are already being used off-label by people chasing performance and longevity claims, well ahead of the safety data catching up.

Is MOTS-c FDA approved, and what does that mean for safety oversight?

No. MOTS-c does not appear in the FDA's Drugs@FDA database of approved drug products ^[4]. It is not an approved drug for any indication, human or otherwise. That matters for the long-term side effect question because FDA approval is exactly the process that would normally generate the safety data you're asking about: Phase 1 dose-escalation and safety trials, Phase 2 efficacy and side-effect monitoring, Phase 3 large-scale trials with adverse event tracking, and post-market surveillance. None of that has happened for MOTS-c in a way that's produced public results. MOTS-c also isn't on FDA's 503A bulk drug substances list for compounding ^[5], nor the 503B list for outsourcing facilities ^[6]. FDA maintains a list of bulk substances nominated for compounding consideration, and reviewing that list against MOTS-c is worth doing before assuming any compounding pharmacy relationship confers regulatory approval, because it doesn't automatically ^[7]. Under 21 U.S.C. 353a, compounded drugs get an exemption from full FDA approval requirements only under specific conditions tied to a valid prescription and bulk substances that meet compendial or 503A-list criteria ^[8]. A pharmacy being willing to compound something is not the same as FDA having reviewed its long-term safety.

What does the animal and cell research actually show about MOTS-c's effects on the body?

A lot, mechanistically, across a surprising range of tissues. None of it is long-term human safety data, but it's worth knowing what's actually been studied, because it explains both the enthusiasm and the caution. Metabolic and diabetes-related findings dominate the literature. A 2022 Pharmacological Research study found MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model ^[9]. A 2025 Experimental & Molecular Medicine paper reports that MOTS-c prevents pancreatic islet cell senescence to delay diabetes onset in the model studied ^[10]. A 2023 Metabolites paper is titled, plainly, 'MOTS-c Functionally Prevents Metabolic Disorders' ^[11], and a 2023 Diabetes & Metabolism Journal review connects MOTS-c to diabetes and aging-related disease pathways broadly ^[12]. Muscle research is the second big cluster, and it's directly relevant to the 'exercise mimetic' claims you'll see in supplement marketing. A 2021 paper in the American Journal of Physiology found MOTS-c reduces myostatin and muscle atrophy signaling in the model tested ^[13]. A 2024 AJP-Endocrinology and Metabolism paper found the peptide attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration ^[14]. A 2022 Peptides paper found MOTS-c promotes muscle differentiation in vitro, meaning in cultured cells, not in a living animal or person ^[15]. A 2024 iScience paper identified a direct mechanism: MOTS-c binds and activates an enzyme called CK2 to modulate skeletal muscle function ^[16]. Beyond metabolism and muscle, the peptide has been studied in cancer biology (a 2024 Advanced Science paper found MOTS-c suppresses ovarian cancer progression via a ubiquitination pathway) ^[17], lung injury and fibrosis [18, 19], bone metabolism ^[18], osteoarthritis ^[19], viral infection (a 2024 Gut paper on antiviral effects during hepatitis B infection) ^[20], cardiac disease ^[21], and even cell membrane repair ^[22]. This is a peptide with its hands in a lot of biological pathways. That breadth is exactly why 'long-term side effects in humans' is such an open question: a molecule that touches this many systems could plausibly have off-target effects in people that a mouse study of one tissue would never catch.

Does the evidence support MOTS-c being an 'exercise in a pill' or exercise mimetic?

It supports the idea that MOTS-c is involved in how the body responds to exercise stress at a molecular level. It does not support the marketing claim that taking MOTS-c replicates the benefits of exercise. The strongest basis for the exercise-mimetic framing comes from a 2018 Cell Metabolism paper showing that MOTS-c translocates to the nucleus in response to metabolic stress and regulates nuclear gene expression there ^[23], and a 2022 Diabetes & Metabolism Journal review specifically on 'Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)' ^[24]. A 2021 review in Biochimica et Biophysica Acta on mitochondrial-derived peptides and exercise lays out the biological logic: MOTS-c levels and activity appear connected to exercise-induced stress signaling ^[25]. But connected-to is not the same as sufficient-for. These papers describe MOTS-c as part of the signaling cascade that happens during exercise, in animal and cell models. They do not show that injecting MOTS-c into a person who isn't exercising produces the cardiovascular, mitochondrial biogenesis, bone density, and mood effects that actual exercise produces. 'Exercise in a pill' is a marketing shorthand, not a finding any of these papers make. If you want the metabolic benefits that show up in the mouse literature, the closest thing we actually know works in humans is exercise itself.

Are there any known toxicity or organ damage risks with MOTS-c?

No published human toxicology data exists to answer this directly. What's available is scattered organ-specific animal research, some of it protective in direction, which is reassuring but not the same as a formal toxicology package. A 2025 Redox Biology paper found MOTS-c attenuates lung ischemia-reperfusion injury in the model studied, via a nuclear translocation mechanism ^[26]. A 2023 European Journal of Pharmacology paper found MOTS-c suppresses ferroptosis (a form of cell death) and reduces acute lung injury from myocardial ischemia reperfusion ^[27]. A 2025 American Journal of Respiratory Cell and Molecular Biology paper found MOTS-c promotes glycolysis via an AMPK-HIF-1a-PFKFB3 pathway to reduce cardiopulmonary bypass-induced lung injury ^[28]. A 2025 Cardiovascular Drugs and Therapy paper, titled with the question 'MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?', reviews cardiac-protective mechanisms without claiming clinical proof ^[21]. These are protective findings in disease models, which is the opposite of a toxicity signal. But protective-in-a-mouse-model-of-injury and safe-for-long-term-use-in-healthy-humans are different claims, and the literature only supports the first one. There is one paper that should temper any blanket 'it's protective everywhere' read: a 2018 Rejuvenation Research paper titled 'Mitochondrial-Derived Peptides Exacerbate Senescence' ^[29]. This is about mitochondrial-derived peptides as a class, and the specific conditions matter a lot, but it's a real signal that this peptide family's effects aren't uniformly beneficial across every cellular context. Nobody has reconciled that finding with the protective-effect literature in a human trial.

What side effects have been reported by people using MOTS-c off-label?

There is no systematic reporting infrastructure for this, which is itself the honest answer. MOTS-c isn't FDA-approved, so there's no formal adverse event reporting system (like FAERS) tracking side effects the way there would be for an approved drug. Anecdotal reports online mention injection site irritation, mild nausea, or transient dizziness, consistent with what you'd expect from a subcutaneously injected peptide generally, but these are self-reports, not data from a controlled study, and they should be weighted accordingly. The 2026 Sports Medicine review of peptide therapies used for musculoskeletal injury and athletic performance is one of the only sources that engages with real-world use patterns of unapproved peptides in this space ^[3], and its framing (grouping MOTS-c with other unapproved peptides under a safety-and-efficacy lens) is itself informative: researchers are treating this as an open safety question, not a settled one. If you're tracking your own experience, standard practice is to log injection site reactions, sleep, appetite, and any unusual symptoms, and to stop and talk to a physician if anything concerning shows up. That's basic self-monitoring, not a substitute for the trial data that doesn't exist yet.

How does MOTS-c's safety profile compare to other mitochondrial-derived peptides?

MOTS-c is one of several mitochondrial-derived peptides identified so far (humanin is another well-known one), and the safety picture across the class looks similarly early-stage: promising cell and rodent mechanism data, thin-to-absent human trial data.

The 2019 BioEssays review describes MOTS-c as 'a mitochondrial-encoded regulator of the nucleus,' framing it as a genuinely novel signaling molecule rather than a simple metabolic tweak ^[30]. That novelty is part of why it's interesting to researchers and part of why nobody can yet tell you what happens if a healthy person takes it for two years. New mechanism, thin safety record: that combination is true across most of this peptide class, more than MOTS-c.

What dosing and formulation factors affect side effect risk?

Dose, purity, and injection technique all affect side effect risk in ways that are somewhat predictable from general peptide pharmacology, even without MOTS-c-specific long-term data. Because there's no approved dosing regimen, anyone using MOTS-c off-label is working from protocols that haven't been validated in controlled human trials. Sourcing quality matters enormously here, arguably more than for approved drugs, because there's no FDA batch oversight catching contamination or mislabeled concentration. A peptide sold as MOTS-c with the wrong purity, wrong concentration, or bacterial contamination could easily cause side effects that get wrongly attributed to MOTS-c itself. If you're evaluating a source, our mots-c peptide buy guide covers what separates a legitimate provider-reviewed route from a sketchy one, and our mots-c dosage page and mots-c 10mg dosage calculator walk through how people typically approach dosing decisions, though again, none of this is FDA-validated dosing. Injection technique itself carries its own small, well-understood risk profile (site irritation, rarely infection if technique is poor), covered in more detail on our mots-c peptide injection page. None of that is MOTS-c-specific; it's true of any subcutaneous peptide.

Who should avoid MOTS-c or be especially cautious?

Given the total absence of human long-term safety data, the more conservative framing is: anyone with a serious medical condition, anyone pregnant or trying to conceive, anyone on medications with narrow safety margins, and anyone under 18 should not be experimenting with MOTS-c outside of a clinical trial setting, full stop. The cancer-related finding deserves specific mention here. A 2024 Advanced Science paper found MOTS-c suppresses ovarian cancer progression in the model studied, through a mechanism involving USP7-mediated LARS1 deubiquitination ^[17]. That's a potentially interesting anti-cancer signal in one specific cancer model. It is absolutely not evidence that MOTS-c is safe to self-administer if you have any cancer history or risk, and it's also not evidence it's unsafe. It's simply too early and too narrow a finding to act on either way outside of oncology research. Anyone with a history of unusual cellular senescence concerns, given the 2018 Rejuvenation Research signal about mitochondrial-derived peptides exacerbating senescence in some contexts ^[29], should also be cautious, though that finding is about the peptide class broadly and its relevance to MOTS-c specifically in humans hasn't been worked out.

What would it take to actually know the long-term side effects of MOTS-c?

A real answer requires the standard drug development pipeline that MOTS-c hasn't gone through yet: a Phase 1 human safety trial with dose escalation and adverse event monitoring, ideally followed by Phase 2 trials tracking side effects over months in the target population, and eventually post-market surveillance if it were ever approved. None of the roughly 30 studies referenced in this article are that trial. They're rodent metabolic studies [1, 9, 11], cell mechanism papers [16, 24], disease-model studies in lung, bone, cartilage, and liver [19, 20, 21, 33], and reviews synthesizing the mechanism story [2, 12, 26, 32]. That's a genuinely rich mechanistic picture. A 2025 Scientific Reports paper, for instance, found MOTS-c mimics exercise-related signaling to combat diabetic liver fibrosis in the model tested, via a Keap1-Nrf2-Smad2/3 pathway ^[31], which is a sophisticated finding about mechanism, not a statement about human safety over years of use. Until a registered human trial with a real follow-up period gets published, 'long term side effects of MOTS-c' has one honest answer: unknown. Our mots-c side effects page covers the shorter-term picture in more depth, and our mots-c hub page is the place to start if you want the full evidence landscape before deciding anything.

What's the practical takeaway if you're considering MOTS-c anyway?

If you're going to use it despite the evidence gap, do it with your eyes open about what's actually been shown and what hasn't. Treat any claim of 'proven safe long-term' as false; that claim doesn't have a citation because the study doesn't exist. Work with a physician who knows your full history, not a source that just wants to sell you a vial. Ask specifically about interactions with any diabetes medication, given how much of the mechanistic literature centers on glucose and insulin pathways [1, 9, 11]. Keep the dose conservative and don't stack multiple experimental peptides at once, because if something goes wrong, you'll have no way to know which compound caused it. MOTS-c Co doesn't compound or manufacture anything; we cover the evidence and route readers to a provider-reviewed path with pharmacy partners who handle sourcing and fulfillment, which at least gets you standardized purity and dosing accuracy, the two variables you can actually control while the safety trials catch up to the hype.

Frequently asked questions

Has MOTS-c been tested in a long-term human clinical trial?

No. Every source reviewed here is a rodent study, a cell-culture study, or a mechanistic review. No published trial has tracked human participants taking MOTS-c over months or years to document side effects, meaning the honest current status is 'unknown,' not 'safe' or 'unsafe.'

Is MOTS-c approved by the FDA?

No. MOTS-c does not appear in Drugs@FDA, the agency's database of approved drug products, and it is not on FDA's 503A or 503B bulk drug substance lists for compounding, which means it hasn't gone through the approval process that would generate formal human safety data.

Can MOTS-c cause cancer or affect existing cancer risk?

The one cancer-related study found MOTS-c suppressed ovarian cancer progression in a specific model, via a mechanism involving USP7-mediated LARS1 deubiquitination (Advanced Science, 2024). That's a narrow, model-specific finding, not evidence about human cancer risk from taking MOTS-c, in either direction.

Does MOTS-c really work like exercise, or is that just marketing?

The research shows MOTS-c is involved in exercise-related metabolic stress signaling in animal and cell models, including nuclear gene regulation. It does not show that taking MOTS-c replicates the cardiovascular, muscular, and mood benefits of actually exercising. 'Exercise mimetic' overstates what the studies demonstrate.

What are the most common short-term side effects reported with MOTS-c?

Formal adverse-event data doesn't exist since there's no FDA reporting system for an unapproved peptide. Anecdotal, self-reported issues include injection site irritation, mild nausea, and dizziness, consistent with general peptide injection experience rather than anything specific to MOTS-c's mechanism.

Is MOTS-c legal to buy and use?

It falls into a gray zone. It isn't FDA-approved, isn't on the 503A or 503B bulk compounding lists, and there's no dedicated law banning personal possession. Compounding pharmacies operate under 21 U.S.C. 353a, which requires specific conditions tied to prescriptions and approved bulk substances.

Are there any organ damage risks from long-term MOTS-c use?

No human toxicology data exists. Rodent studies have found MOTS-c protective against lung injury, ischemia-reperfusion damage, and osteoarthritis-related cartilage degradation in specific injury models, but protective-in-a-disease-model is not the same claim as safe-for-long-term-use-in-healthy-people.

Does MOTS-c interact with diabetes medications?

No formal interaction studies in humans exist. Because a large share of the rodent literature centers on glucose and insulin pathways, including hyperglycemia and insulin resistance models, anyone on diabetes medication should treat this as a real unknown and discuss it with a physician before combining them.

Can MOTS-c worsen aging-related cellular processes instead of helping them?

A 2018 Rejuvenation Research paper found that mitochondrial-derived peptides, as a class, can exacerbate senescence markers in certain contexts. This is a genuine caution signal that hasn't been fully reconciled with the mostly protective findings reported elsewhere in the MOTS-c literature.

Is there a difference in safety between MOTS-c and other mitochondrial-derived peptides like humanin?

Both are early-stage: strong rodent and cell mechanism data, minimal human trial data. The sources reviewed here don't provide detailed humanin safety comparisons, so a direct side-by-side safety claim between the two peptides isn't supportable from current published evidence.

How would researchers eventually determine MOTS-c's long-term safety?

Through the standard pipeline: a Phase 1 human dose-escalation safety trial, then Phase 2 trials monitoring adverse events over months in a target population, then post-market surveillance if ever approved. None of that has happened yet for MOTS-c.

Should someone with a family history of cancer avoid MOTS-c?

There's no data to make a firm recommendation either way. One study found an anti-cancer signal in a specific ovarian cancer model, but this hasn't been tested in humans or across other cancer types. Anyone with a cancer history or strong family risk should discuss this specifically with an oncologist before use.

Sources

1. Cell Metabolism, 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in a mouse model
2. Frontiers in Endocrinology, 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation
3. Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance
4. FDA, Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product
5. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the 503A bulk drug substances list for compounding, which MOTS-c is not on
6. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the 503B bulk drug substances list for outsourcing facilities, which MOTS-c is not on
7. FDA, bulk drug substances nominated for compounding (current list): FDA maintains a public list of bulk substances nominated for compounding consideration
8. Cornell Law, 21 U.S.C. 353a: Compounded drugs receive an exemption from full approval requirements only under specific prescription and substance conditions
9. Pharmacological Research, 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model
10. Experimental & Molecular Medicine, 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in the model studied
11. Metabolites, 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders in the studied model
12. Diabetes & Metabolism Journal, 2023 (PMID 36824008): Reviews MOTS-c's connection to diabetes and aging-related disease pathways
13. American Journal of Physiology-Endocrinology and Metabolism, 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in the model tested
14. American Journal of Physiology-Endocrinology and Metabolism, 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
15. Peptides, 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro, in cultured cells
16. iScience, 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
17. Advanced Science, 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression via a USP7-mediated LARS1 deubiquitination mechanism in the model studied
18. European Journal of Pharmacology, 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and reduces acute lung injury from myocardial ischemia reperfusion via PPARgamma signaling
19. Mitochondrion, 2023 (PMID 37307934): MOTS-c is identified as a potential anti-pulmonary fibrosis factor derived from mitochondria
20. Frontiers in Physiology, 2023 (PMID 37200834): Reviews MOTS-c's role in the regulation of bone metabolism
21. Free Radical Biology & Medicine, 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in osteoarthritis via an Nrf2-dependent mechanism
22. Gut, 2024 (PMID 37788894): MOTS-c has an antiviral role during hepatitis B infection via mitochondrial remodelling
23. Cardiovascular Drugs and Therapy, 2025 (PMID 40172798): Reviews MOTS-c's proposed cardiac-protective mechanisms in diabetic cardiomyopathy
24. Theranostics, 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation to the membrane
25. Cell Metabolism, 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress
26. Diabetes & Metabolism Journal, 2022 (PMID 35656563): Reviews MOTS-c's connection to exercise and mitohormesis signaling
27. Biochimica et Biophysica Acta - General Subjects, 2021 (PMID 34520826): Reviews the relationship between mitochondrial-derived peptides and exercise
28. Redox Biology, 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation
29. American Journal of Respiratory Cell and Molecular Biology, 2025 (PMID 40035775): MOTS-c promotes glycolysis via AMPK-HIF-1a-PFKFB3 pathway to reduce cardiopulmonary bypass-induced lung injury
30. Rejuvenation Research, 2018 (PMID 30058454): Mitochondrial-derived peptides can exacerbate senescence markers in certain contexts
31. BioEssays, 2019 (PMID 31378979): Describes MOTS-c as a mitochondrial-encoded regulator of the nucleus
32. Scientific Reports, 2025 (PMID 40425777): MOTS-c mimics exercise-related signaling to combat diabetic liver fibrosis via Keap1-Nrf2-Smad2/3 pathway